| 000 | 01734 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250514212019.0 | ||
| 264 | 0 | _c20050125 | |
| 008 | 200501s 0 0 eng d | ||
| 022 | _a0090-8258 | ||
| 024 | 7 |
_a10.1016/j.ygyno.2004.08.028 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aBerkenblit, Anna | |
| 245 | 0 | 0 |
_aA phase II trial of weekly docetaxel in patients with platinum-resistant epithelial ovarian, primary peritoneal serous cancer, or fallopian tube cancer. _h[electronic resource] |
| 260 |
_bGynecologic oncology _cDec 2004 |
||
| 300 |
_a624-31 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Phytogenic _xadministration & dosage |
| 650 | 0 | 4 |
_aCystadenocarcinoma, Serous _xdrug therapy |
| 650 | 0 | 4 | _aDocetaxel |
| 650 | 0 | 4 | _aDrug Administration Schedule |
| 650 | 0 | 4 | _aDrug Resistance, Neoplasm |
| 650 | 0 | 4 |
_aFallopian Tube Neoplasms _xdrug therapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aOrganoplatinum Compounds _xtherapeutic use |
| 650 | 0 | 4 |
_aOvarian Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aPeritoneal Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aTaxoids _xadministration & dosage |
| 700 | 1 | _aSeiden, Michael V | |
| 700 | 1 | _aMatulonis, Ursula A | |
| 700 | 1 | _aPenson, Richard T | |
| 700 | 1 | _aKrasner, Carolyn N | |
| 700 | 1 | _aRoche, Maria | |
| 700 | 1 | _aMezzetti, Lisa | |
| 700 | 1 | _aAtkinson, Tina | |
| 700 | 1 | _aCannistra, Stephen A | |
| 773 | 0 |
_tGynecologic oncology _gvol. 95 _gno. 3 _gp. 624-31 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.ygyno.2004.08.028 _zAvailable from publisher's website |
| 999 |
_c15266767 _d15266767 |
||